For several years, she has been providing companies solutions in identification, evaluation, valuation, negotiation and strategy for partnering in or out. She has an extensive deal sheet ranging from company acquisitions to Phase III compounds and from preclinical candidates to technologies. Dr.. Pullan also served as President and CEO of Viriome, Inc. and on the board of directors of Paloma Pharmaceuticals, Inc.
She writes a free monthly newsletter Pullan’s Pieces, with tidbits of science and business for about 3,000 readers. Interested readers may sign up at www.pullanconsulting.com.
Dr. Pullan earned her Ph.D. in biochemistry from the University of California, Riverside and her BS degree in chemistry with a biology minor at the University of Utah.
Full biographies, unique experience, expertise & accomplishments of each advisory board member:
- Neil J. Campbell,
M.A., M.B.A. – Chairman - Kevin Carroll
- Edward L. Erickson
- Daniel D'Agostino
- Nigel Gaymond, M.A.
- David M. Koeninger
- Udo Klein, Ph.D.
- Stefan Loren, Ph.D.
- Kevin Nickels
- Rick Pierce
- Robin Pratt, Ph.D.
- Linda M. Pullan, Ph.D.
- Dane Saglio, C.P.A.
- Peter G. Savas
- Chris Ward
- Ruth Williams, Esq.
Linda M. Pullan, Ph.D. offers biotech and pharmaceutical companies consulting in all aspects of partnering through Pullan Consulting (www.pullanconsulting.com). Linda has a Ph.D. in Biochemistry and a B.S. in Chemistry. Linda has more than 20 years of drug industry experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca.
She contributed to and led teams that put AstraZeneca’s multi-billion dollar antipsychotic Seroquel® and other molecules into development. Her business development experiences began with in-licensing technology and early drug candidates in all therapeutic areas at what is now AstraZeneca, and Dr. Pullan continued as head of oncology and hematology licensing for Amgen. She then joined Kosan Biosciences as VP of Business Development and experienced all the tasks of out-licensing and business development in a small company.
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||